Promising antidiabetic drug

We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion. It is an innovative drug that is in the first phase of research when it is first used in humans. The first drug administrations are behind us, we continue with the next doses. We plan to complete 1 part of SAD (single ascending dose) at the end of July.

More and more people are suffering from type II diabetes, it is a civilization disease, we challenge it with new drugs in the hope of full success. The BRG Center hopes to participate in many such Polish projects.

Go back

News

Dr Jarosław Długołęcki

We are pleased to welcome a new member of the BRG medical expert team. Mr Jarosław Długołęcki, (M.D.) - doctor with extensive knowledge and 16-years’ experience in clinical studies at the international level.

Read more …

Badania kliniczne faz wczesnych szczepionek – wyzwania w obliczu nowych zagrożeń

Szczepienia ochronne niezaprzeczalnie należą do jednych z najbardziej przełomowych odkryć nowoczesnej medycyny.

Read more …

Publication in the Biotechnology magazine

We invite you to read our publication in the Biotechnology magazine - the largest industry portal in Poland, the latest information from the sectors: biotechnology, cosmetology, pharmacy and technologies.

Read more …

Promising antidiabetic drug

We have started an interesting study with a promising antidiabetic drug. The drug is designed in the form of prolonged-action tablets, which action leads to increased insulin secretion.

 

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲